title: 18FDG PET in oncology: the best and the worst (Review).
abstract: The clinical added-value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) in the management of oncology patients is increasingly documented. In the present review, we discuss both the benefits and the limitations of 18FDG PET in different cancers. Considering the literature data and our own experience, we also indicate the best clinical approach to optimize the use of metabolic imaging in oncology.
authors.affiliation: Department of Nuclear Medicine, Jules Bordet Cancer Institute, PET-CT Unit, 1000 Brussels, Belgium. tarik.bel@swing.be
authors.forename: Tarik
authors.initials: T
authors.lastname: Belhocine
authors.forename: Karoline
authors.initials: K
authors.lastname: Spaepen
authors.forename: Michelle
authors.initials: M
authors.lastname: Dusart
authors.forename: Catherine
authors.initials: C
authors.lastname: Castaigne
authors.forename: Kristof
authors.initials: K
authors.lastname: Muylle
authors.forename: Pierre
authors.initials: P
authors.lastname: Bourgeois
authors.forename: Daniel
authors.initials: D
authors.lastname: Bourgeois
authors.forename: Lawrence
authors.initials: L
authors.lastname: Dierickx
authors.forename: Patrick
authors.initials: P
authors.lastname: Flamen
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18